Pesquisar Neste Blog

quinta-feira, 29 de setembro de 2011

Alzheimer's Protein Kills Nerve Cells in Nose; Animal Study May Suggest Way to Rescue Cells from Disease

ScienceDaily (Sep. 28, 2011) — A protein linked to Alzheimer's disease kills nerve cells that detect odors, according to an animal study in the Sept. 28 issue of The Journal of Neuroscience. The findings shed light on why people with Alzheimer's disease often lose their sense of smell early on in the course of the disease.

"Deficits in odor detection and discrimination are among the earliest symptoms of Alzheimer's disease, suggesting that the sense of smell can potentially serve as a 'canary in the coal mine' for early diagnosis of the disease," said Leonardo Belluscio, PhD, of the National Institute of Neurological Disorders and Stroke, who led the study. "The changes taking place in the olfactory system as a result of Alzheimer's disease may be similar to those in other regions of the brain but appear more rapidly" he added.

Researchers once thought that protein plaques commonly seen in the brains of people with Alzheimer's disease were responsible for killing off nerve cells, causing disruptions in memory -- a hallmark of the disease. The plaques are primarily derived from a protein called amyloid precursor protein (APP). The new study suggests that APP alone -- in the absence of the plaques -- may be to blame for the death of nerve cells.

In the new study, Belluscio and his colleagues genetically manipulated mice to produce high levels of a mutated version of human APP in olfactory nerve cells. The mutated form of the protein is seen in some people with early-onset Alzheimer's disease, a rare form that runs in families and strikes before age 65.

The researchers found that mice making mutant APP had four times as much olfactory nerve cell death by three weeks of age compared with normal mice. Although the cells that produced mutant APP died, the neighboring cells -- that did not have mutant APP -- survived. The cell death also occurred in the absence of amyloid plaques. Together, this showed that the cell death was initiated from within the cells making the mutant APP, not from plaques outside the cells. When the researchers blocked the olfactory nerve cells from producing high levels of the mutant precursor protein, more cells lived.

"Reducing APP production suppressed the widespread loss of nerve cells, suggesting that such disease-related death of nerve cells could potentially be stopped," Belluscio said.

"Together, these results support the hypothesis that amyloid proteins are involved in the degeneration of the brain that occurs with Alzheimer's disease," said Donald Wilson, PhD, of New York University School of Medicine and the Nathan Kline Institute for Psychiatric Research, an olfactory system expert who was unaffiliated with the study. "Further, they provide an exciting opportunity to explore how to prevent or reverse the events that lead to cell death and, ultimately, dementia."

Women Have Stronger Immune Systems Than Men -- And It's All Down to X-Chromosome Related microRNA

ScienceDaily (Sep. 28, 2011) — As anyone familiar with the phrase 'man-flu' will know women consider themselves to be the more robust side of the species when it comes to health and illness. Now new research, published in BioEssays, seems to support the idea. The research focuses on the role of MicroRNAs encoded on the X chromosome to explain why women have stronger immune systems to men and are less likely to develop cancer.
New research on the role of MicroRNAs encoded on the X chromosome helps explain why women have stronger immune systems to men and are less likely to develop cancer.
The research, led by Dr Claude Libert from Ghent University in Belgium, focused on MicroRNA, tiny strains of ribonucleic acid which alongside DNA and proteins, make up the three major macromolecules that are essential for all known forms of life.

"Statistics show that in humans, as with other mammals, females live longer than males and are more able to fight off shock episodes from sepsis, infection or trauma," said Libert. "We believe this is due to the X chromosome which in humans contains 10% of all microRNAs detected so far in the genome. The roles of many remain unknown, but several X chromosome-located strands of microRNA have important functions in immunity and cancer."

Dr Libert's team proposes that the biological mechanisms of the X chromosome have a strong impact on an individual's genes, known as genetic imprinting, which gives an immunological advantage to females. To develop their hypothesis the team produced a detailed map of all described microRNAs which have a role in immune functions and cancer in both human and mouse X chromosomes.

"We believe this immunological advantage is due to the silencing of X-linked genes by these microRNAs," said Libert. "Gene silencing and inactivation skewing are known mechanisms which affect X-linked genes and may influence X-linked microRNAs in the same way."

This genetic silencing leaves males at an immunological disadvantage as a male has only one X-chromosome. The Y-Chomosone contains fewer genes so if the genes involved in immunity are silenced maternally the male is left with no compensating genetic information.

"How this unique form of genetic inheritance influences X-chromosone linked microRNAs will be a challenge for researchers for years to come," concluded Libert, "not only from an evolutionary point of view, but also for scientists investigating the causes and cures of disease."

quarta-feira, 28 de setembro de 2011

World Rabies Day: watch the new FAOcast on Dop Population Management


logo
image
text
link



Veterinary Medicine September Issue




Your September issue of Veterinary Medicine Digital is now available,
click HERE to view.

Click the Renew button below to update your subscription information.
Click Here to Renew
  

Check out our Web site featuring veterinary news, business, medicine, and team information.

Nova droga trata câncer de próstata com metástase



Um novo medicamento para câncer de próstata em estágio avançado pode melhorar a qualidade de vida dos pacientes, diminuindo as dores, e fazê-los viverem mais.


Os resultados de estudos de fase 3 (últimos antes de uma droga ser aprovada) foram apresentados no fim de semana no congresso da Sociedade Europeia de Oncologia, em Estocolmo (Suécia). 

O remédio Alpharadin foi testado em 922 pacientes com metástase óssea. Dos pacientes com câncer de próstata, até 40% têm metástase. Em 90% dos casos, o tumor se espalha para os ossos, principalmente na coluna, na bacia e no fêmur. Isso gera muita dor e pode deixar os pacientes incapazes de realizarem suas atividades diárias. 

"O problema é o diagnóstico tardio. Muitos pacientes ainda têm preconceito com o exame de toque retal", afirma o oncologista André Murad, do HC da Universidade Federal de Minas Gerais e do Hospital Lifecenter, que participou do estudo. 

TESTE 

O medicamento foi testado em 20 países, incluindo o Brasil. Seis centros médicos do país, entre eles o Hospital das Clínicas da USP e o Hospital do Câncer de Barretos, estavam envolvidos na pesquisa. 

Os pacientes foram divididos em dois grupos: um deles tomava o remédio e o outro recebia placebo, sem que ninguém soubesse quem recebia o tratamento ativo. 

Aqueles que tomaram o Alpharadin tiveram taxas de mortalidade 30% menores e uma sobrevida média de 14 meses, em comparação com 11 meses do outro grupo. 

Como os resultados preliminares foram bons, o estudo foi interrompido para que os pacientes do grupo-placebo recebessem a droga. 

TELEGUIADO 

O remédio é um radiofármaco formado por partículas radioativas que têm afinidade pelas células ósseas -da mesma forma que o iodo radioativo tem preferência pela tireoide, por exemplo. 

"Essas partículas se dirigem às células da metástase, depositam-se nelas e as destroem. É quase um míssil teleguiado", compara Murad. 

Segundo Gustavo Guimarães, chefe do setor de urologia do Hospital A.C. Camargo, outros radiofármacos causam diminuição de glóbulos brancos e de plaquetas, e não aumentam a sobrevida. 

"Esse novo remédio é mais preciso, age milimetricamente nas células malignas." 

Marcos Dall'Oglio, professor da USP e chefe do departamento de uro-oncologia do HC, afirma que a droga pode adiar a quimioterapia, o que é importante no caso de pacientes idosos, que não suportam esse tratamento. A radioterapia comum também pode afetar os tecidos normais e a produção de sangue. 

Os efeitos colaterais mais comuns, segundo o estudo, foram diarreia e náusea. 

O aposentado Raimundo Nonato da Fonseca, 83, de Belo Horizonte, foi um dos voluntários da pesquisa e afirma não ter tido nenhuma reação adversa ao remédio. 

"Por causa das dores, não caminhava. Hoje durmo melhor, como bastante bem e estou engordando. Graças a Deus me dei bem." 

A Bayer HealthCare Pharmaceuticals, que produz a droga, prevê seu lançamento no Brasil em 2013.